Cancer clinical trials in the region Pays de la Loire
440 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Endometrial cancer
#NCT06952504
#2024-519331-42-00
Required histologic sub types
Endometrioid adenocarcinoma
Serous adenocarcinoma
Clear cell carcinoma
Dedifferentiated and undifferentiated endometrial ...
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSI/dMMR
Excluded previous treatments at localized stage
Immunotherapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
10 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06824467
#2023-508015-23-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required FIGO stages
Stage III
Stage IV
Required number of previous lines of therapy for current stage of disease
1
2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06712355
#2024-515765-34-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
Bispecific T-cell engager antibodies
7 recruiting sites
BioNTech SE
Phase 3
Colon cancer
Rectal cancer
#NCT06107920
#2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Chemotherapy
Radiotherapy
28 recruiting sites
Hôpital universitaire de Rouen
Phase 3
Breast cancer
#NCT06435429
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Jazz Pharmaceuticals
Phase 3
Prostate cancer
#NCT07213674
#2025-520555-89-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Amgen
Phase 3
Breast cancer
#NCT06982521
#2025-523083-21-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
None
1
2
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
Hormone therapy
Excluded genetic anomalies
AKT
PTEN
Excluded previous treatments at localized stage
Immunotherapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
18 recruiting sites
Relay Therapeutics, Inc.
Phase 3
Endometrial cancer
#NCT06340568
#2023-507525-42-00
Required histologic sub types
Endometrioid adenocarcinoma
Serous adenocarcinoma
Clear cell carcinoma
Dedifferentiated and undifferentiated endometrial ...
Carcinosarcoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Immunotherapy
Chemotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
8 recruiting sites
BioNTech SE
Phase 3
Breast cancer
#NCT06380751
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
BRCA 1/2
PALB2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3
Endometrial cancer
#NCT06712472
#2023-503886-44-00
Required histologic sub types
Endometrioid adenocarcinoma
Serous adenocarcinoma
Clear cell carcinoma
Dedifferentiated and undifferentiated endometrial ...
Carcinosarcoma
Required FIGO stages
Stage I
Stage II
Stage III
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Chemotherapy
Radiotherapy
Excluded genetic anomalies
MSI/dMMR
POLE
14 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris